Genomics

She's called the Biotech Barbie.

Um, she's just, uh, launched a company called, uh, Origin, uh, Genomics.

It's-- obviously, it's about gene editing in the embryo, and her pitch, her moralizing pitch is to try and eradicate all disease and tackle hereditary, um, problems and conditions.

The reason this is s- interesting, um, is firstly because she's been here before with something she actually called, uh, historically, a Manhattan Genomic- Genomics.

Um, and, uh, that was, uh, launched in 2023, um, around the launch of the, uh, Oppenheimer film, hence why she also called herself the Biotech Barbie.

She's trying to, you know, dovetail on those two pieces-

[laughs] Um, but she's, she's a fascinating person.

She w- she left university in Toronto, she's a Chinese Canadian, to take a scholarship from the Peter Thiel Scholarship, which gives people $100,000, uh, to leave university and pursue a scientific avenue.

And Acorn co-founder Herman Hauser asks how Europe can fund its next generation of global companies.

We also speak to the Wetherill Institute of Molecular Medicine, Immunocore, Genomics, and many more.

The ideas are here.

What will it take to build on them? Oxford Plus, partnered with Mishkondorea and sponsored by HSBC Innovation Banking.